Business Update
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
17 FEBRUARY 2016
2016 HALF-YEAR FINANCIAL RESULTS
SIGNIFICANT REVENUE GROWTH DELIVERS $1.1M EBIT FOR FIRST HALF OF FINANCIAL YEAR 2016
SUMMARY OF FIRST HALF RESULTS FOR FINANCIAL YEAR 2016 (1H16)
Revenue from ordinary activities up 109% to A$13.0m compared to A$6.2m in Previous
Corresponding Period (PCP)
EBIT of A$1.1m (PCP: EBIT loss of -A$2.9m)
Net Profit after tax of A$2.6m, including an income tax benefit of A$1.5m (PCP: Net Loss
after tax of -A$2.7m)
Record Clinical Trials sales contracts signed for the half-year of US$16.6m (A$23.1m)
Since 1 January 2016, US$4.0m (A$5.6m) of Clinical Trials sales contracts have been
signed, taking total sales contracts signed FYTD to US$20.6m (A$28.7m)
Outlook: Strong contracted revenue position for both FY16 and FY17 years.
Positive EBIT expected in 2H16
MELBOURNE, AUSTRALIA: Leading cognitive science company, Cogstate (ASX.CGS), has today released
its Appendix 4D and financial results for the half-year ended 31 December 2015.
FINANCIAL RESULTS OVERVIEW
Metric
1H16 (A$m) actual
1H15 (A$m) actual
% change
Clinical Trials Revenue
12.2
5.6
120%
Total Revenue
13.0
6.2
109%
Profit Before Tax
1.1
-2.9
Profit After Tax
2.6
-2.7
Cogstate reported a substantial increase in half-on-half revenue, with underlying revenue (excluding passthrough cost recoveries) for 1H16 of A$13.0m, up 109% on A$6.2m in 1H15. The main revenue driver was
the increase in Clinical Trials business, which accounted for A$12.2m (92%) of underlying revenue. The
increase in Clinical Trials revenue is attributed to an enhanced commercial business development team,
strong operational delivery and positive industry trends. These factors have resulted in a significant increase
in sales contracts over the last 18 months; including a record US$16.6m (A$23.1m) of new sales contracts
(1)
signed during 1H16, compared to US$13.4m (A$14.4m) in 1H15. .
Gross Profit of $7.5m in 1H16 was up 224% on $2.3m in PCP. This was largely driven by the strong
performance from Clinical Trials (up $4.3m), but also growth from Precision Recruitment (up $0.4m). The
Gross Profit margin for the Clinical Trials business of 57.3% in 1H16 was down on 60.7% recorded in 2H15
but within management’s target range of 57-60%.
(1)
Contracts are denominated in US$. The A$ equivalent is based on the prevailing spot rate at the time of signing the individual contracts
Cogstate reported an EBIT of A$1.1m, an improvement of $4.0m compared to the negative EBIT of A$2.9m
in PCP.
Looking forward, the company expects to report positive EBIT in 2H16 and continues to make good
progress towards growing contracted future revenue with A$15.3m already secured for FY17.
Cogstate’s total contracted revenue pipeline currently stands at A$52.1m.
SUMMARY FINANCIAL RESULTS
HALF JUST
COMPLETED
PREVIOUS HALF
PREVIOUS
CORRESPONDING
HALF
1ST HALF
FY16
$’000,000
2ND HALF
FY15
$’000,000
1ST HALF
FY15
$’000,000
Clinical Trials Revenue
12.24
9.62
5.57
Clinical Trials Cost of Sales
-5.23
-3.78
-2.95
Clinical Trials Gross Margin
7.01
5.84
2.62
Clinical Trials Net Recovery of Pass-through Costs
0.01
0.07
0.10
Total Clinical Trials Contribution
7.02
5.91
2.72
Precision Recruitment Contribution
0.60
0.21
0.23
Healthcare Contribution
-0.16
-0.13
-0.10
Sport Contribution
-0.03
-0.02
-0.09
Total Business Unit Contribution
7.42
5.97
2.76
Overhead Costs – Continuing Operations
-6.46
-6.71
-5.62
-
-
-0.34
Other Income
0.10
0.70
0.43
EBITA
1.06
-0.04
-2.77
Amortisation
0.00
-0.14
-0.14
Impairment of Assets
0.00
-2.16
0.00
EBIT
1.06
-2.35
-2.92
Interest Income
0.04
0.04
0.08
Interest Expense
0.00
-0.04
-0.02
Profit / (Loss) Before Tax
1.10
-2.35
-2.86
Income Tax Benefit / (Expense)
1.46
-0.05
0.20
Profit / (Loss) After Tax
2.56
-2.40
-2.66
Overhead Costs – Discontinued Operations
At 31 December 2015, Cogstate brought to account the future tax benefit associated with carry-forward
losses from its USA operations. Predominantly the carry-forward losses relate to the operations of the Axon
Sports business, the disposal of which was concluded in November 2014.
Cogstate’s USA operations are no longer impacted by the losses from the Axon Sports business and the
Clinical Trials operations in the USA are profitable. Therefore, the decision was made to recognize the
income tax benefit associated with the carry-forward tax losses of A$6.88m, which resulted in the recognition
of a tax benefit of A$1.46m in the half-year to 31 December 2015.
The Company reported an A$0.2m cash inflow from operating activities in 1H16 and as at 31 December
2015 had cash holdings of A$5.1m.
COMMENTARY
“These strong half-year financial results highlight that the upward momentum in our business continues”,
said Brad O’Connor, Chief Executive of Cogstate. “We have grown our contracted revenue pipeline further in
2016, we have delivered a positive 1H16 EBIT in line with guidance, and we are on track to return to a
positive full year EBIT in FY16.
“The combined effects of our enhanced commercial sales organisation and continued operational delivery,
along with positive industry trends for research into Alzheimer’s disease and major psychiatric disorders
have resulted in continued growth of Clinical Trials sales contracts. Having signed US$16.6m of sales
contracts in 1H16, we have signed an additional US$4.0m of new contracts in the 6 weeks since 1 January
2016.
“At the date of this announcement, we have secured A$23.3m of Clinical Trials revenue so far for the 2016
financial year, of which A$12.2m was recorded in 1H16. Our contracted Clinical Trials revenue pipeline
currently totals A$52.1m, up 105% on the contracted revenue pipeline at this time last year. “
Contracted Clinical Trials Revenue
2
As at 17 February 2016
As at 30 June 2015
As at 18 February 2015
Year 1
FY16
A$23.3m
FY16
A$10.9m
FY15
A$12.0m
Year 2
FY17
A$15.3m
FY17
A$6.5m
FY16
A$5.5m
Years 3 – 5
FY18 – FY21
A$13.5m
FY18 – FY20
A$4.0m
FY17 – FY19
A$7.9m
Total
(2)
A$52.1m
A$21.4m
A$25.4m
Contracts are denominated in US$. Spot rate at respective dates have been used to calculate the A$ equivalent. The rate used at 17 February 2016
was 0.718, 30 June 2015 was 0.765 and 18 February 2015 was 0.78.
In a release dated 22 December 2015, Cogstate announced that it had, at that time, A$45.0m of contracted
future Clinical Trials revenue, of which it expected A$23.0m to be recognised in the FY16 year. Since that
announcement, Cogstate has been advised of patient recruitment delays for three large clinical trials, which
will impact Cogstate by delaying some activities, milestones and associated revenue. The delay in expected
revenue recognition will push some revenue into the FY17 year. However, it is important to note that: 1) This
is a timing issue only, with the full amount of contracted revenue still expected to be recognised for the
studies affected; and 2) As the table above highlights, the amount of contracted revenue that is expected to
be recognised in FY16 has increased to A$23.3m, up from A$23.0m as at 22 December 2015, with
additional contract wins since that date more than offsetting the impact of study milestone delays.
$ Millions
Clinical Trials Contracts & Revenue
26
24
22
20
18
16
14
12
10
8
6
4
2
FY09
FY10
Value of Sales Contracts signed, US$
FY11
FY12
FY13
Clinical Trials Revenue, A$
FY14
FY15
FY16 YTD
Projected Clinical Trials Revenue, A$
(based on contracts signed as at 17 Feb 16)
ABOUT COGSTATE
Cogstate Ltd (ASX:CGS) is a leading cognitive science company delivering software and services to
optimise the measurement of cognition in clinical trials, academic research, healthcare and brain injury.
Cogstate is a pioneer in commercialising rapid, reliable and highly sensitive computerised cognitive tests and
provides expert support for traditional neurological assessments to drive higher quality outcome measures.
Cogstate clients include the world’s leading biopharmaceutical companies; military and elite sporting
organisations; physicians and patients; renowned academic institutions and public-private partnerships. With
more than 90 employees and a global network of expert neurophysiologist consultants across 25 countries,
the unique intersection of science, innovation and delivery is at the core of everything we do.
In our clinical trials business, Cogstate provides both software and professional services for clinical research
programs seeking to demonstrate a drug’s impact on cognition. Cogstate solutions span the clinical trial
process from study design to final statistical analysis; and our latest innovation, Precision Recruitment™, is
an online pre-screening portal that accelerates the identification of qualified clinical trial participants in highneed indications such as Alzheimer’s disease.
For further information contact:
Brad O’Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com
Kyahn Williamson
Buchan Consulting
0401 018 828
kwilliamson@buchanwe.com.au
Share your feedback
Discover